Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1409885
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative)
Description:
Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market
While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.
Features and benefits
- Analysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader interviews
- Epidemiological forecasts of breast cancer incidence and prevalence for the period 2010–19 in the seven major pharmaceutical markets
- Segmentation of incident cases by age group, menopausal status, stage of disease and subtype
- In-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and disease stage
Highlights
Herceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse, retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflecting the lack of clinical data showing that switching to Tykerb is beneficial.
Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of this indication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g. Sanofi Aventis’s iniparib), even if it retains its breast cancer indication.
The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior in metastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if they are to achieve extensive uptake.
Your key questions answered
- Validate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake for new products
- Understand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populations
- Enhance commercial positioning by increasing understanding of current dynamics within the breast cancer market
While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.
Features and benefits
- Analysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader interviews
- Epidemiological forecasts of breast cancer incidence and prevalence for the period 2010–19 in the seven major pharmaceutical markets
- Segmentation of incident cases by age group, menopausal status, stage of disease and subtype
- In-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and disease stage
Highlights
Herceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse, retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflecting the lack of clinical data showing that switching to Tykerb is beneficial.
Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of this indication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g. Sanofi Aventis’s iniparib), even if it retains its breast cancer indication.
The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior in metastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if they are to achieve extensive uptake.
Your key questions answered
- Validate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake for new products
- Understand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populations
- Enhance commercial positioning by increasing understanding of current dynamics within the breast cancer market
Contents:
Overview
Catalyst
Summary
Executive Summary
Scope of the analysis
Datamonitor insight into the hormone receptor-negative breast cancer market
Contributing experts
1. Introduction and Scope
Coverage of the Stakeholder Insight Survey
2. Epidemiology
Introduction and background
Key points
Disease definition and diagnosis criteria
Global variation and historical trends
Risk factors
Epidemiologic forecasting of breast cancer
Description of methods
Epidemiologic Forecast Results
Discussion
Conclusions
3. Disease overview
Introduction
Patient segmentation
4. Treatment options
Introduction
5. Treatment Trends: Stage I–III
Triple-negative breast cancer
HER-2-positive breast cancer
6. Treatment Trends: Stage IV and Relapse
Triple-negative breast cancer
HER-2-positive breast cancer
7. Future Treatment
Late-phase pipeline products overview
Future treatment scenarios
BIBLIOGRAPHY
Chapter 2. Epidemiology
Chapter 3. Disease Overview
Chapter 4. Treatment Options
Chapter 5. Treatment Trends: Stage I–III Breast Cancer
Chapter 6. Treatment Trends: Stage IV and Relapsed Breast Cancer
Chapter 7. Future Treatment
APPENDIX A
Abbreviations
Physician research methodology
Physician sample breakdown
Contributing experts
APPENDIX B
The survey questionnaire
Datamonitor consulting
Disclaimer
Catalyst
Summary
Executive Summary
Scope of the analysis
Datamonitor insight into the hormone receptor-negative breast cancer market
Contributing experts
1. Introduction and Scope
Coverage of the Stakeholder Insight Survey
2. Epidemiology
Introduction and background
Key points
Disease definition and diagnosis criteria
Global variation and historical trends
Risk factors
Epidemiologic forecasting of breast cancer
Description of methods
Epidemiologic Forecast Results
Discussion
Conclusions
3. Disease overview
Introduction
Patient segmentation
4. Treatment options
Introduction
5. Treatment Trends: Stage I–III
Triple-negative breast cancer
HER-2-positive breast cancer
6. Treatment Trends: Stage IV and Relapse
Triple-negative breast cancer
HER-2-positive breast cancer
7. Future Treatment
Late-phase pipeline products overview
Future treatment scenarios
BIBLIOGRAPHY
Chapter 2. Epidemiology
Chapter 3. Disease Overview
Chapter 4. Treatment Options
Chapter 5. Treatment Trends: Stage I–III Breast Cancer
Chapter 6. Treatment Trends: Stage IV and Relapsed Breast Cancer
Chapter 7. Future Treatment
APPENDIX A
Abbreviations
Physician research methodology
Physician sample breakdown
Contributing experts
APPENDIX B
The survey questionnaire
Datamonitor consulting
Disclaimer
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1409885
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Wednesday, June 19, 2013
6:39:57 PM
6:39:57 PM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative)
Web Address
http://www.researchandmarkets.com/reports/1409885
Office Code
OC8DIQQMLUSWYY
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price |
|---|---|---|
| Hard Copy |
|
EUR 11,703 + EUR€ 50.00 Shipping/Handling * |
| Electronic (PDF) - Enterprisewide |
|
EUR 29,065 |
| Electronic (PDF) - Single User |
|
EUR 11,626 |
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Wednesday, June 19, 2013
6:39:57 PM
6:39:57 PM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp